CONFIDENTIAL DRAFT FOR PURPOSES OF SETTLEMENT DISCUSSIONS ONLY September 3, 2013 William H. Gates Dear Bill: RE: Letter of Agreement Regarding Purchase of Partnership Interest This letter sets forth the agreement by and between you, William H. Gates ("Gates"), and me, Dr. Boris Nikolic ("Dr. Nikolic"), with respect to the purchase by Gates from Dr. Nikolic of Dr. Nikolic's interest in a partnership, under the terms of which we discussed potential investment in a range up to $100 Million in certain investments discovered and researched by Dr. Nikolic (the "Investment Entity"). Only two of such investments, totaling Twenty Million Dollars, as detailed below, were ever made. The partnership was formed effective April 1, 2013. We now agree to dissolve and wind up the Investment Entity and Gates shall purchase from Dr. Nikolic Dr. Nikolic's interest in the Investment Entity. Gates and Dr. Nikolic have agreed as follows: Dissolution and Winding Up the Partnership SE251912 vl EFTA_R1_00438087 EFTA01961275

- 2 - EFTA_R1_00436088 EFTA01961276

- 3 - EFTA_R1_00436089 EFTA01961277

- 4 - EFTA_R1_00436090 EFTA01961278

Sale and Purchase of Interest in Investment Entity - 5 - EFTA_R1_00438091 EFTA01961279

- 6 - EFTA_R1_00436092 EFTA01961280

- 7 - EFTA_R1_00436093 EFTA01961281

- 8 - EFTA_R1_00436094 EFTA01961282

1 I ( 1 t 1 1 t 1 1 — 9 — EFTA_R1_00436095 EFTA01961283

- 10 - EFTA_R1_00436096 EFTA01961284

I ( EFTA_R1_00436097 EFTA01961285

- 12 - EFTA_R1_00436098 EFTA01961286

- 13 - EFTA_R1_00436099 EFTA01961287

- 14 - EFTA_R1_00436100 EFTA01961288

- IS - EFTA_R1_00436101 EFTA01961289

- 16 - EFTA_R1_00436102 EFTA01961290

- 17 - EFTA_R1_00436103 EFTA01961291

- Is - EFTA_R1_00436104 EFTA01961292

- 19 - EFTA_R1_00436105 EFTA01961293

Advance 1 I - 20 - EFTA_R1_00436106 EFTA01961294

t 1 ( I ( 1 - 21 - EFTA_R1_00436107 EFTA01961295

- 22 - EFTA_R1_00436108 EFTA01961296

- 23 - EFTA_R1_00436109 EFTA01961297

- 24 - EFTA_R1_00436110 EFTA01961298

- 25 - EFTA_R1_00436111 EFTA01961299

- 26 - EFTA_R1_00436112 EFTA01961300

- 27 - EFTA_R1_00436113 EFTA01961301

- 28 - EFTA_R1_00436114 EFTA01961302

I - 29 - EFTA_R1_00436115 EFTA01961303

- 30 - EFTA_R1_00436116 EFTA01961304

- 31 - EFTA_R1_00436117 EFTA01961305

- 32 - EFTA_R1_00436118 EFTA01961306

- 33 - EFTA_R1_00436119 EFTA01961307

- 34 - EFTA_R1_00436120 EFTA01961308

- 35 - EFTA_R1_00436121 EFTA01961309

- 36 - EFTA_R1_00436122 EFTA01961310

- 37 - EFTA_R1_00436123 EFTA01961311

- 38 - EFTA_R1_00436124 EFTA01961312

- 39 - EFTA_R1_00436125 EFTA01961313

- 40 - EFTA_R1_00436126 EFTA01961314

t ( 1 ( -41- EFTA_R1_00436127 EFTA01961315

- 41 - EFTA_R1_00436128 EFTA01961316

Foundation Medicine, Inc. and ResearchGate GmbH - 43 - EFTA_R1_00436129 EFTA01961317

44 EFTA_R1_00436130 EFTA01961318

- 45 - EFTA_R1_00436131 EFTA01961319

- 46 - EFTA_R1_00436132 EFTA01961320

- 47 - EFTA_R1_00436133 EFTA01961321

- 48 - EFTA_R1_00436134 EFTA01961322

- 49 - EFTA_R1_00436135 EFTA01961323

( t - 50 - E FTA_R 1_00436136 EFTA01961324

-51- EFTA_R1_00436137 EFTA01961325

- 52 - EFTA_R1_00436138 EFTA01961326

- 53 - E FTA_R 1_00436139 EFTA01961327

- 54 - EFTA_R1_00436140 EFTA01961328

- 55 - EFTA_R1_00436141 EFTA01961329

- 56 - EFTA_R1_00436142 EFTA01961330

- 57 - EFTA_R1_00436143 EFTA01961331

- 58 - EFTA_R1_00436144 EFTA01961332

- 59 - EFTA_R1_00436145 EFTA01961333

- 60 - EFTA_R1_00436146 EFTA01961334

-61- EFTA_R1_00436147 EFTA01961335

- 62 - EFTA_R1_00436148 EFTA01961336

Investment Entity Payment Demands At any time and from time to time commencing on the date hereof and continuing through and including September 3, 2016 (the "Payment Period"), Dr. Nikolic shall have the right, exercisable by written notice to Gates, to demand payment of the increase in value in respect of all or a portion of the Foundation Medicine Investment and/or up to fifty percent (50%) or a portion of fifty percent (50%) of the ResearchGate Investment (an "Investment Entity Payment Demand"). Dr. Nikolic may deliver to Gates up to an aggregate of four (4) Investment Entity Payment Demands during the Payment Period. The amount of each Investment Entity Payment Demand shall be equal to the sum of: I. The portion of the Foundation Medicine Investment, expressed as a percentage, as to which Dr. Nikolic in his sole discretion elects to make such Investment Entity Payment Demand (provided it is equal to or smaller than any percentage remaining after any prior partial percentage Investment Entity Payment Demands), multiplied by the difference of (a) the fair market value of the Foundation Medicine Investment (including all dividends, payments, distributions, securities and other items of value at any time previously or hereafter distributed or paid by Foundation Medicine in respect of such investment) as of the date of such Investment Entity Payment Demand, less (b) Ten Million Dollars (510,000,000) and less any prior payments, including the Advances; and 2. The portion of the ResearchGate Investment, expressed as a percentage, as to which Dr. Nikolic in his sole discretion elects to make such Investment Entity Payment Demand (provided it is equal to or smaller than any percentage remaining after any prior partial percentage Investment Entity Payment Demands), multiplied by the difference of (a) the fair market value of the ResearchGate Investment (including all dividends, payments, distributions, securities and other items of value at any time previously or hereafter distributed or paid by ResearchGate in - 63 - EFTA_R1_00438149 EFTA01961337

3. respect of such investment) as of the date of such Investment Entity Payment Demand, less (b) Ten Million Dollars ($10,000,000) and any prior payments, including the Advances. The portion of the Foundation Medicine Investment as to which any Investment Entity Payment Demand may be made at any given time may not exceed the difference of 100% less the aggregate percentage of the Foundation Medicine Investment as to which all then prior Investment Entity Payment Demands were paid by Gates to Dr. Nikolic. The portion of the ResearchGate Investment as to which any Investment Entity Payment Demand may be made at any given time may not exceed the difference of 50% less the aggregate percentage of the ResearchGate Investment as to which all then prior Investment Entity Payment Demands were paid by Gates to Dr. Nikolic. In the event that all of the shares of Foundation Medicine or ResearchGate are acquired by a third party entity, not affiliated with either of the parties to this Agreement, then the remaining interest of Dr. Nikolic under this Agreement, in the acquired company, shall be calculated immediately following the date on which the final interest of the Gates Purchaser is known and such amount shall be paid out by Gates to Dr. Nikolic and Dr. Nikolic shall have no further claim under this Agreement as to that particular investment. Fair Market Values - 64 - EFTA_R1_00436150 EFTA01961338

- 65 - EFTA_R1_00436151 EFTA01961339

- 66 - EFTA_R1_00436152 EFTA01961340

- 67 - EFTA_R1_00436153 EFTA01961341

- 68 - EFTA_R1_00436154 EFTA01961342

- 69 - EFTA_R1_00436155 EFTA01961343

- 70 - EFTA_R1_00436156 EFTA01961344

- 71 - EFTA_R1_00436157 EFTA01961345

- 72 - EFTA_R1_00436158 EFTA01961346

- 73 - EFTA_R1_00436159 EFTA01961347

- 74 - EFTA_R1_00436160 EFTA01961348

- 75 - EFTA_R1_00436161 EFTA01961349

- 76 - EFTA_R1_00436162 EFTA01961350

- 77 - EFTA_R1_00436163 EFTA01961351

- 78 - EFTA_R1_00436164 EFTA01961352

- 79 - EFTA_R1_00436165 EFTA01961353

- 80 - EFTA_R1_00436166 EFTA01961354

_g1 - EFTA_R1_00436167 EFTA01961355

- 82 - EFTA_R1_00436168 EFTA01961356

- 83 - EFTA_R1_00436169 EFTA01961357

- 84 - EFTA_R1_00436170 EFTA01961358

- 85 - EFTA_R1_00436171 EFTA01961359

- 86 - EFTA_R1_00436172 EFTA01961360

- 87 - EFTA_R1_00436173 EFTA01961361

- 88 - EFTA_R1_00436174 EFTA01961362

- 89 - EFTA_R1_00436175 EFTA01961363

- 90 - EFTA_R1_00436176 EFTA01961364

- 91 - EFTA_R1_00436177 EFTA01961365

- 92 - EFTA_R1_00436178 EFTA01961366

- 93 - EFTA_R1_00436179 EFTA01961367

- 94 - EFTA_R1_00436180 EFTA01961368

- 95 - EFTA_R1_00436181 EFTA01961369

- 96 - EFTA_R1_00436182 EFTA01961370

- 97 - EFTA_R1_00436183 EFTA01961371

- 98 - EFTA_R1_00436184 EFTA01961372

- 99 - EFTA_R1_00436185 EFTA01961373

- 100 - EFTA_R1_00436186 EFTA01961374